Literature DB >> 12030615

The low dose dexamethasone suppression test: effect of time of administration and dose.

C Barton1, S March, G A Wittert.   

Abstract

The dexamethasone suppression test (DST) is used to determine the sensitivity of the hypothalamic-pituitary-adrenal axis (HPA-axis) to negative feedback. Dexamethasone is usually administered at 23:00 h or at midnight but this is often not convenient. The aim of this study was to determine whether the administration of dexamethasone at 21:00 h as compared to 23:00 h would alter the degree to which 08:00 h plasma cortisol was suppressed the following morning. Three healthy males (mean+/-SE: 32+/-7 yr) and 3 healthy females (mean+/-SE: 35+/-7 yr) took part in the study. Each subject was orally administered 1 of 3 doses of dexamethasone (0.25 mg, 0.5 mg, or 1.0 mg) on 3 separate occasions in random order at least a week apart. Each dose of dexamethasone was taken at either 21:00 h or 23:00 h so that each subject underwent 6 tests. The differences in cortisol suppression between times and doses of dexamethasone were assessed using Analysis of Variance. Plasma cortisol was suppressed less in response to 0.25 mg dexamethasone at both 21:00 h and 23:00 h as compared with doses of dexamethasone of 0.5 mg or 1.0 mg (p=0.004). Suppression of plasma cortisol in response to each dose of dexamethasone was similar regardless of the timing of dexamethasone administration (p=0.5). We conclude that in healthy subjects 0.25 mg dexamethasone suppresses plasma cortisol less than either 0.5 mg or 1.0 mg and that 0.5 mg dexamethasone suppresses plasma cortisol to a similar extent as 1.0 mg dexamethasone. Moreover, changing the administration time of dexamethasone from 23:00 h to 21:00 h does not effect the degree to which cortisol is suppressed in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030615     DOI: 10.1007/BF03344008

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  6 in total

Review 1.  Cushing's syndrome: a review of diagnostic tests.

Authors:  L Crapo
Journal:  Metabolism       Date:  1979-09       Impact factor: 8.694

Review 2.  Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome--recommendations for a protocol for biochemistry laboratories.

Authors:  P J Wood; J H Barth; D B Freedman; L Perry; B Sheridan
Journal:  Ann Clin Biochem       Date:  1997-05       Impact factor: 2.057

3.  Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome.

Authors:  D C Aron; H Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1997-06       Impact factor: 5.958

4.  Disrupted 24-hour patterns of cortisol secretion in psychotic depression.

Authors:  E J Sachar; L Hellman; H P Roffwarg; F S Halpern; D K Fukushima; T F Gallagher
Journal:  Arch Gen Psychiatry       Date:  1973-01

Review 5.  Psychoneuroendocrine research in depression. I. Hormone levels of different neuroendocrine axes and the dexamethasone suppression test.

Authors:  R Rupprecht; K P Lesch
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

6.  The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder.

Authors:  T R Kosten; V Wahby; E Giller; J Mason
Journal:  Biol Psychiatry       Date:  1990-10-15       Impact factor: 13.382

  6 in total
  2 in total

1.  Gender difference in adrenal sensitivity to ACTH is abolished in type 2 diabetes.

Authors:  Lisa Arnetz; Neda Rajamand Ekberg; Kerstin Brismar; Michael Alvarsson
Journal:  Endocr Connect       Date:  2015-03-06       Impact factor: 3.335

Review 2.  Biological markers in clinical psychological research - A systematic framework applied to HPA axis regulation in PTSD.

Authors:  Sinha Engel; Hannah Klusmann; Sebastian Laufer; Claudia Kapp; Sarah Schumacher; Christine Knaevelsrud
Journal:  Compr Psychoneuroendocrinol       Date:  2022-06-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.